Infectious Disease Department

Instituts

Asthmaklinik - CVK

Projects

• A PHASE III, RANDOMIZED, DOUBLE?BLIND, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF DPC 083 VERSUS NELFIN
• A Phase II Study of ABT-378/Ritonavir and Efavirenz in HIV Infected Subjects expirienced with Multiple Protease Inh
• A Phase IIIB open label clinical study to evaluate sefaty of Tenofovir Disoproxil Fumarate (Tenofovir DF) in the t
• A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 (Proleukin®) in Patients
• A phase III b randomised, open-label, multicenter study to evaluate the safety and efficacy of a triple combinatio
• A phase III open-label safety study of T-20/Ro 29-9800 (HIV-1 fusion inhibitor) in combination with oral antiretrov
• A phase III study: Operation combined with radiation versus radiation alone in patients with stage I-IIIA small cel
• A phase IV study with PegIntron and Rebetrol in coinfected patients with chronic hepatitis C
• A placebo-controlled, dose escalation study in HIV-1 infected subjects to characterize the safety, tolerability and
• A prospective, non-blinded non-comparative phase-I-study of BAY 38-3441 administered as an intravenous infusion fo
• A randomized, open-label, two arm trial to compare the safety and antiretroviral efficacy of GW 433908/ritonavir QD
• An open label, phase II study of ammprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected subjects
• An open-label, randomized, parallel group pharmacokinetics trial of tipranvir/ritonavir (TPV/RTV), alone or in comb
• An uncontrolled phase II study evaluating antitumor efficacy and safety of BAY 59-8862 in Patients with Taxane resi
• Atazanavir (BMS-232632) For HIV Infected Individuals: An Early Access Program Phase: Illb
• C. pneumoniae - endothelial cell interaction
• CAPNETZ Kofinanzierung
• ClinSurv
• DUPONT PHARMA DMP 266 (SUSTIVA TM) Expanded Access Programm-Germany
• Die Bedeutung von IL-15 für die pulmonale Immunabwehr
• Efficacy and Safety of Trizivir plus Efavirenz (Quad-Therapy) Over 72 Weeks Versus Quad Therapy for 24 Weeks Follow
• Endothelzellinfektio
• Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination wi
• Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination wi
• Linezolid
• Linezolid
• MOXIRAPID
• Malaria Epidemiologie
• MedikatStudie
• Mol.Differnzier
• Moxifloxacin CAP
• Moxifloxacin HAP
• Moxifloxacin MAP
• NBL III - TP 3.3.1.A - Dr. Hippenstiel
• Neoadjuvant Chemotherapy Protocol of Docetaxel/Carboplatin in the Treatment of Stage IIIA/IIIB NSCLC
• PMN-Interaktion mit Endothel und Epithelzellmonolayer
• Phosphodiesterases and endothelial cell function
• Randomized Phase II Study of Gemcitabin/Cisplatin followed by Docetaxel vs Gemcitabin / Docetaxel in Patients with
• Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low dose ritonavir (TPV/R
• SCH 417690: Rising Multiple Dose Assessment of Saefety, Tolerance, Pharmacokinetics, and Pharmacodynamics in HIV-1
• Serokonverter
• Standardized Cannabis Extract versus Delta-9-TC in Cancer Patients
• Surveillance der HIV-Krankhei
• Unters.AIDS-Pat
• community acquired pneumonia network
• pfcrt und Chloroquinresistenz

If the list does not contain any entry, the request was executed without results